This article is more than 5 years old. Information may no longer be current.
ATA issues guidelines for anaplastic thyroid cancer management
Click Here to Manage Email Alerts
The American Thyroid Association has released the first set of comprehensive guidelines for the management of anaplastic thyroid cancer, a rare but lethal form of thyroid cancer.
Members of the American Thyroid Association (ATA) task force compiled a list of 65 recommendations based on relevant literature.
Bryan R. Haugen
“The American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer is a remarkable and comprehensive document that distills the literature and task force expertise into a useful guide for providers of patients with this aggressive cancer. The focused therapeutic approaches, as well as the inclusion of palliative care and ethical issues into this document, is a real advance for our field,” ATA president and professor of medicine and pathology; head of the division of endocrinology, metabolism and diabetes at the University of Colorado School of Medicine, Bryan R. Haugen, MD, said in a press release.
According to the guidelines published in Thyroid, the ATA task force sought to address the following: diagnosis, initial evaluation, establishment of treatment goals, approaches to locoregional disease (i.e., surgery, radiotherapy, systemic therapy, and supportive care during active therapy), approaches to advanced/metastatic disease, palliative care options, surveillance and long-term monitoring, and ethical issues regarding end-of-life.
For more information:
Smallridge RC. Thyroid. 2012; doi: 10.1089/thy.2012.0302.
Disclosure: See the study for a full list of disclosures.